Northern Trust’s Windtree Therapeutics WINT Stock Holding History

Northern Trust’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$8.53K	–	4631
2022 Q4	$8.53K	Hold	1	–	–	﹤0.01%	4588
2022 Q3	$15K	Hold	1	–	–	﹤0.01%	4594
2022 Q2	$21K	Hold	1	–	–	﹤0.01%	4619
2022 Q1	$62K	Sell	1 -1	-50%	-$52.5K	﹤0.01%	4487
2021 Q4	$114K	Hold	2	–	–	﹤0.01%	4382
2021 Q3	$148K	Buy	2 +1	+100%	+$85.1K	﹤0.01%	4288
2021 Q2	$149K	Hold	1	–	–	﹤0.01%	4248
2021 Q1	$125K	Sell	1 -1	-50%	-$216K	﹤0.01%	4236
2020 Q4	$371K	Hold	2	–	–	﹤0.01%	3800
2020 Q3	$449K	Buy	2 +1	+100%	+$336K	﹤0.01%	3643
2020 Q2	$439K	Buy	+1	New	+$317K	﹤0.01%	3588

Other funds holding WINT

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust's WINT Position: Q1 2023 in Review

Northern Trust sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 1 share — an estimated $8.53K sold.

Northern Trust first reported a position in WINT in Q2 2020 and held it in 11 quarters. The position peaked at $449K in Q3 2020. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

Northern Trust reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
Northern Trust sold 1 Windtree Therapeutics share in Q1 2023, an estimated $8.53K.
Northern Trust first reported a position in Windtree Therapeutics in Q2 2020 and held it in 11 quarters.
Northern Trust's Windtree Therapeutics position peaked at $449K in Q3 2020.
2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Northern Trust's 13F filing for Q1 2023, filed 15 May 2023.